What have we learned about vaginal infections and preterm birth?
暂无分享,去创建一个
[1] Brett A. Collins,et al. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. , 2001, The New England journal of medicine.
[2] J. Paavonen,et al. Vaginal Clindamycin in Preventing Preterm Birth and Peripartal Infections in Asymptomatic Women With Bacterial Vaginosis: A Randomized, Controlled Trial , 2001, Obstetrics and gynecology.
[3] J. Peipert,et al. Screening for bacterial vaginosis in pregnancy. , 2001, American journal of preventive medicine.
[4] M. Dombrowski,et al. The Preterm Prediction Study: association between cervical interleukin 6 concentration and spontaneous preterm birth. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. , 2001, American journal of obstetrics and gynecology.
[5] J. Paavonen,et al. A randomised controlled trial of vaginal clindamycin for early pregnancy bacterial vaginosis , 2000, BJOG : an international journal of obstetrics and gynaecology.
[6] G. Thurnau,et al. The Preterm Prediction Study: association of second-trimester genitourinary chlamydia infection with subsequent spontaneous preterm birth. , 2000, American journal of obstetrics and gynecology.
[7] B. Sibai,et al. Vaginal fetal fibronectin measurements from 8 to 22 weeks' gestation and subsequent spontaneous preterm birth. , 2000, American journal of obstetrics and gynecology.
[8] M. Dombrowski,et al. The preterm prediction study: granulocyte colony-stimulating factor and spontaneous preterm birth. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. , 2000, American journal of obstetrics and gynecology.
[9] Ichael,et al. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. , 2000, The New England journal of medicine.
[10] A. Helwig,et al. Bacterial vaginosis in pregnancy and the risk of prematurity: a meta-analysis. , 1999, The Journal of family practice.
[11] H. Bruinse,et al. Prophylactic administration of clindamycin 2 % vaginal cream to reduce the incidence of spontaneous preterm birth in women with an increased recurrence risk: a randomised placebo‐controlled double‐blind trial , 1999, British journal of obstetrics and gynaecology.
[12] H. McClean. Impact of metronidazole therapy on preterm birth in women with bacterial vaginosis flora , 1998, British journal of obstetrics and gynaecology.
[13] P. McDonald,et al. Impact of metronidazole therapy on preterm birth in women with bacterial vaginosis flora (Gardnerella vaginalis): a randomised, placebo controlled trial , 1997, British journal of obstetrics and gynaecology.
[14] R. Steele. Reduced Incidence of Preterm Delivery with Metronidazole and Erythromycin in Women with Bacterial Vaginosis , 1996, Clinical pediatrics.
[15] E. Thom,et al. The Preterm Prediction Study: Fetal Fibronectin, Bacterial Vaginosis, and Peripartum Infection , 1996, Obstetrics and gynecology.
[16] S. Hillier,et al. Intravaginal clindamycin treatment for bacterial vaginosis: effects on preterm delivery and low birth weight. , 1995, American journal of obstetrics and gynecology.
[17] E. Thom,et al. The preterm prediction study: significance of vaginal infections. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. , 1995, American journal of obstetrics and gynecology.
[18] J. Carey,et al. Outcome of the Vaginal Infections and Prematurity Study: results of a clinical trial of erythromycin among pregnant women colonized with group B streptococci. , 1995, American Journal of Obstetrics and Gynecology.
[19] N. Padian,et al. Plasma Cell Endometritis in Women With Symptomatic Bacterial Vaginosis , 1995, Obstetrics and gynecology.
[20] John A. Albritton,et al. Effect of metronidazole in patients with preterm birth in preceding pregnancy and bacterial vaginosis: a placebo-controlled, double-blind study. , 1994, American journal of obstetrics and gynecology.
[21] J. French,et al. Bacterial vaginosis is associated with prematurity and vaginal fluid mucinase and sialidase: results of a controlled trial of topical clindamycin cream. , 1994, American journal of obstetrics and gynecology.
[22] W. Poole,et al. A randomized placebo‐controlled trial of erythromycin for the treatment of Ureaplasma urealyticum to prevent premature delivery , 1992 .
[23] N. Kiviat,et al. Microbiologic causes and neonatal outcomes associated with chorioamnion infection. , 1991, American journal of obstetrics and gynecology.
[24] W. Poole,et al. A randomized placebo-controlled trial of erythromycin for the treatment of Ureaplasma urealyticum to prevent premature delivery , 1991 .
[25] N. Kiviat,et al. A case‐control study of chorioamnionic infection and histologic chorioamnionitis in prematurity , 1989, The New England journal of medicine.
[26] J. Feldman,et al. Risk factors for prematurity and premature rupture of membranes: a prospective study of the vaginal flora in pregnancy. , 1984, American journal of obstetrics and gynecology.
[27] P. Hardy,et al. PREVALENCE OF SIX SEXUALLY TRANSMITTED DISEASE AGENTS AMONG PREGNANT INNER-CITY ADOLESCENTS AND PREGNANCY OUTCOME , 1984, The Lancet.
[28] C. Doré,et al. Effect of intravaginal clindamycin cream on pregnancy outcome and on abnormal vaginal microbial flora of pregnant women. , 2000, Infectious diseases in obstetrics and gynecology.
[29] R. Gibbs,et al. Double-Blind Placebo-Controlled Treatment Trial of Chlamydia trachomatis Endocervical Infections in Pregnant Women , 1997, Infectious diseases in obstetrics and gynecology.